Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CCR6 | P51684 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11065049 | 0.86 | DRD1 (0.56) | DRD1ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL2536969 | 0.79 | DRD1 (0.47) | DRD1ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL2539666 | 0.78 | LMNA (0.44) | DRD1ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL13264261 | 0.78 | DRD1 (0.68) | DRD1ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL8266849 | 0.76 | ALDH1A1 (0.49) | DRD1ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL24261088 | 0.74 | DRD1 (0.47) | DRD1ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL5805632 | 0.74 | DRD1 (0.47) | DRD1ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL181946 | 0.74 | DRD1 (0.47) | DRD1ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL157708 | 0.74 | ALOX15 (0.50) | DRD1ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL12444149 | 0.74 | ALOX15 (0.50) | DRD1ALDH1A1MEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 376 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3692101-B1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTR S R L (IT) | 2022-01-12 | — | — | EP | claimed |
| EP-3692101-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | Alfa Instruments S.r.l. (IT) | 2020-08-12 | — | — | EP | claimed |
| CN-105980387-B | Serine/threonine kinase inhibitor | 阵列生物制药公司 | 2019-04-19 | — | — | CN | claimed |
| WO-2019068935-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTRUMENTS S.R.L. (IT) | 2019-04-11 | — | — | WO | claimed |
| US-10154995-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-12-18 | — | — | US | claimed |
| EP-3089788-B1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH INC (US) | 2018-10-24 | — | — | EP | claimed |
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| CN-107652204-A | A kind of epoxides grafting hydrazine reduction prepares and the method for dispersed graphite alkene | 山东理工大学 | 2018-02-02 | — | — | CN | claimed |
| EP-3089980-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2018-01-31 | — | — | EP | claimed |
| US-20170348310-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-12-07 | — | — | US | claimed |
| US-20050187227-A1 | 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-25 | — | — | US | claimed |
| EP-1556372-A2 | SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL) PIPERIDINE AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2005-07-27 | — | — | EP | claimed |
| US-20050026954-A1 | Muscarinic receptor antagonists; overactive bladder, irritable bowel syndrome, chronic obstructive pulmonary disease, and asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-02-03 | — | — | US | claimed |
| WO-2005007645-A1 | SUBSTITUTED 4-AMINO-1-BENZYLPIPERIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2005-01-27 | — | — | WO | claimed |
| US-20040220169-A1 | Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-11-04 | — | — | US | claimed |
| WO-2004056784-A1 | NOVEL CARBOXAMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-08 | — | — | WO | claimed |
| US-20040122014-A1 | Muscarinic M2 receptor antagonists; such as 4-{N-[7-(3-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine; reduced blurred vision, constipation and dry mouth side effects | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-06-24 | — | — | US | claimed |
| WO-2004041806-A2 | SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL) PIPERIDINE AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2004-05-21 | — | — | WO | claimed |
| US-6723743-B1 | TREATING PATIENT SUFFERING FROM RHEUMATOID ARTHRITIS, PSORIASIS, BRONCHIAL ASTHMA, ALZHEIMER'S DISEASE, MYOCARDIAL INFARCTION OR ATHEROSCLEROSIS | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | claimed |
| US-20030032644-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-02-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122014-A1 | Muscarinic M2 receptor antagonists; such as 4-{N-[7-(3-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine; reduced blurred vision, constipation and dry mouth side effects | CHRM2, CHRM1, CHRM3 | DRD1 224/4885ALDH1A1 1429/4885MEN1 2804/4885 |
| US-10154995-B2 | Serine/threonine kinase inhibitors | MAP3K1, TTBK1, MAP3K11 | DRD1 4842/4885ALDH1A1 3719/4885MEN1 1352/4885 |
| US-20050026954-A1 | Muscarinic receptor antagonists; overactive bladder, irritable bowel syndrome, chronic obstructive pulmonary disease, and asthma | CHRM5, CHRM3, CHRM1 | DRD1 265/4885ALDH1A1 1154/4885MEN1 2797/4885 |
| US-20170348310-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, TTBK1, MAP3K11 | DRD1 4842/4885ALDH1A1 3719/4885MEN1 1352/4885 |
| US-20030032644-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, PCTP | DRD1 4514/4885ALDH1A1 2611/4885MEN1 3887/4885 |
| US-20040220169-A1 | Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions | F12, F11, F2 | DRD1 2567/4885ALDH1A1 143/4885MEN1 1638/4885 |
| US-20050187227-A1 | 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition | DPP8, DPP4, DPP7 | DRD1 871/4885ALDH1A1 249/4885MEN1 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.